Option chain shows key data for Calithera Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Calithera Biosciences.

Calithera Biosciences (OTC:CALA) Stock, Option Chain

Calithera Biosciences

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

News

Penny Stocks

Short Sellers

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACCD

ALXO

AMAM

AMRN

APGN

ARBK

BBBY

BCAB

BIOL

BIOR

BOXD

BTCS

CALA

CVAC

DATS

DMTK

ELYS

EURN

FREQ

GMVD

HSKA

IDRA

KRUS

LHDX

LODE

NPCE

OTLY

PBLA

PKBO

POET

PRTY

RAIN

RUBY

RYAM

SatixFy Communications Ltd. Ordinary Share

SATX

SMCI

SMIT

SMMT

TMDI

TUEM

VCEL

VORB

VYNE

Why Bed Bath &amp; Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

ASTR

BITF

FRGT

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

NUWE

SWVL

Gainers


	VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo patient was dosed in Phase 1a/b clinical trial of novel BET inhibitor VYN201.


Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket

Earnings

Eurozone

Commodities

Global

ALBO

AMYT

CERS

CINC

CUTR

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday.

S&amp;P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher

CALITHERA BIOSCIENCES INC by Calithera Biosciences, Inc.

Calithera Biosciences Inc

Calamos Convertible Opportunities and Income Fund - Closed End Fund

CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND

CalAmp Corp

Calamos Alternative Nasdaq & Bond ETF

Calamos Convertible and High Income Fund - Closed End Fund

Calamos Convertible & High Income Fund

Calamos Dynamic Convertible & Income Fund - Closed End Fund

Calamos Dynamic Convertible and Income Fund

Calamos ETF Trust Calamos Antetokounmpo Global Sustainable Equities ETF

Calamos ETF Trust Calamos CEF Income & Arbitrage ETF

Calamos ETF Trust Calamos Convertible Equity Alternative ETF

Calamos ETF Trust Calamos Laddered S&P 500 Structured Alt Protection ETF

Calamos ETF Trust Calamos Nasdaq - 100 Structured Alt Protection ETF -June

Calamos ETF Trust Calamos Nasdaq-100 Structured Alt Protection ETF December

Calamos ETF Trust Calamos Nasdaq-100 Structured Alt Protection ETF September

Calamos ETF Trust Calamos Russell 2000 Structured Alt Protection ETF - October

Calamos ETF Trust Calamos Russell 2000 Structured Alt Protection ETF July

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF - October

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF August

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF December

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF July

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF May

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF November

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF September

Calamos Global Dynamic Income Fund - Closed End Fund

Calamos Global Dynamic Income Fund

Calamos Global Total Return Fund - Closed End Fund

Calamos Global Total Return Fund

Calamos Long/Short Equity & Dynamic Income Trust - Closed End Fund

Calamos L/S Equity & Dynamic Inc Trust

Calamos Strategic Total Return Fund - Closed End Fund

Calamos Strategic Total Return Fund

Calavo Growers Inc

<h3>Gainers</h3>
<ul>
<li>HTG Molecular Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTGM#NASDAQ">HTGM</a>) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million. </li>
<li>Lannett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCI#NYSE">LCI</a>) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today. </li>
<li>Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion. The company's, Q4 earnings came out today. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares rose 12.69% to $0.53. Today's trading volume for this security ended up closing at 1.7 million shares, which is 1118.5 percent of its average volume over the last 100 days. The company's market cap stands at $14.2 million. </li>
<li>Nymox Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMX#NASDAQ">NYMX</a>) stock rose 12.29% to $0.49. The market value of their outstanding shares is at $44.8 million. </li>
<li>Opthea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) stock increased by 10.66% to $5.81. The company's market cap stands at $294.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares fell 12.0% to $1.25 during Wednesday's after-market session. Trading volume for this security closed at 1.2 million, accounting for 398.9% of its average full-day volume over the last 100 days. The company's market cap stands at $211.6 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares decreased by 9.62% to $0.33. The market value of their outstanding shares is at $1.6 million. </li>
<li>Metacrine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCR#NASDAQ">MTCR</a>) stock decreased by 7.7% to $0.48. This security traded at a volume of 157.9K shares come close, making up 46.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $20.4 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock fell 7.43% to $7.85. The market value of their outstanding shares is at $217.1 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares declined by 7.15% to $1.56. The market value of their outstanding shares is at $28.6 million. </li>
<li>Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) stock declined by 6.94% to $8.32. The company's market cap stands at $411.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ALGN

BGXX

HTGM

MTCR

NYMX

PPBT

TERN

VERA

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares increased by 251.2% to $1.83 during Wednesday's regular session. The current volume of 81.8 million shares is 25935.4% of Bright Green's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $310.7 million. </li>
<li>Erytech Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERYP#NASDAQ">ERYP</a>) stock increased by 47.76% to $1.33. Trading volume for Erytech Pharma's stock is 281.1K as of 12:30 EST. This is 628.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $41.2 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 32.93% to $2.22. Quoin Pharmaceuticals's stock is trading at a volume of 13.7 million shares as of 12:30 EST. This is 11076.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.7 million. </li>
<li>Chembio Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>) stock rose 23.47% to $0.44. The current volume of 6.1 million shares is 1457.5% of Chembio Diagnostics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $16.3 million. </li>
<li>F-star Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTX#NASDAQ">FSTX</a>) stock increased by 20.31% to $4.95. As of 12:30 EST, this security is trading at a volume of 1.4 million shares, making up 282.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $108.7 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock moved upwards by 18.96% to $0.69. Aethlon Medical's stock is trading at a volume of 1.1 million shares as of 12:30 EST. This is 109.3% of its average full-day volume over the last 100 days. The company's market cap stands at $15.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) stock decreased by 29.0% to $1.17 during Wednesday's regular session. Taysha Gene Therapies's stock is trading at a volume of 3.6 million shares as of 12:30 EST. This is 431.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $72.7 million. </li>
<li>Invacare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVC#NYSE">IVC</a>) shares decreased by 21.49% to $0.53. The market value of their outstanding shares is at $20.0 million. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) shares decreased by 21.16% to $0.82. The current volume of 594.7K shares is 496.7% of Evelo Biosciences's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $89.8 million. </li>
<li>G Medical Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMVD#NASDAQ">GMVD</a>) stock fell 17.27% to $4.13. As of 12:30 EST, G Medical Innovations's stock is trading at a volume of 241.7K, which is 30.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.8 million. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) shares declined by 16.75% to $1.76. Tenax Therapeutics's stock is trading at a volume of 122.5K shares as of 12:30 EST. This is 35.2% of its average full-day volume over the last 100 days. The company's market cap stands at $4.0 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) stock decreased by 16.44% to $0.34. Calithera Biosciences's stock is trading at a volume of 356.7K shares as of 12:30 EST. This is 136.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

CEMI

ERYP

EVLO

FSTX

QNRX

TENX

TSHA

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Nymox Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMX#NASDAQ">NYMX</a>) shares rose 21.8% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $45.2 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 10.83% to $1.93. The company's market cap stands at $70.6 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock moved upwards by 6.46% to $2.8. The company's market cap stands at $60.9 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock rose 6.28% to $0.57. The market value of their outstanding shares is at $8.0 million. </li>
<li>Athenex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNX#NASDAQ">ATNX</a>) stock rose 5.44% to $0.19. The company's market cap stands at $29.8 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock moved upwards by 5.28% to $0.78. The company's market cap stands at $9.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock fell 9.3% to $3.6 during Monday's after-market session. The market value of their outstanding shares is at $98.8 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares declined by 8.2% to $1.12. The company's market cap stands at $8.8 million. </li>
<li>Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) shares fell 7.41% to $65.5. The company's market cap stands at $2.1 billion. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock declined by 6.39% to $2.2. At the close, Heart Test Laboratories's trading volume reached 2.6 million shares. This is 6319.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $18.3 million. </li>
<li>ASLAN Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) shares declined by 5.77% to $0.64. The market value of their outstanding shares is at $44.6 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) stock fell 5.66% to $0.42. The market value of their outstanding shares is at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASLN

ATNX

BCLI

CELZ

HSCS

ITGR

OKYO

SONN

VRAX

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Vaccitech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VACC#NASDAQ">VACC</a>) shares rose 8.5% to $3.2 during Friday's after-market session. The company's market cap stands at $119.3 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares rose 7.34% to $0.39. The market value of their outstanding shares is at $1.8 million. </li>
<li>Ocuphire Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUP#NASDAQ">OCUP</a>) shares increased by 6.45% to $3.63. The market value of their outstanding shares is at $75.5 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock increased by 6.12% to $0.59. The company's market cap stands at $8.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares rose 5.88% to $1.44. The company's market cap stands at $13.5 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares increased by 4.95% to $3.39. Trading volume for this security closed at 174.7K, accounting for 1.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $716.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock declined by 9.9% to $0.31 during Friday's after-market session. Akanda's trading volume hit 12.9 million shares by close, accounting for 440.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.5 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock declined by 9.76% to $0.79. The market value of their outstanding shares is at $6.5 million. </li>
<li>Zynerba Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYNE#NASDAQ">ZYNE</a>) shares declined by 6.48% to $0.62. The company's market cap stands at $29.1 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) shares decreased by 5.56% to $1.02. Today's trading volume for this security ended up closing at 17.4 million shares, which is 7279.1 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $36.8 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 5.41% to $0.7. The market value of their outstanding shares is at $6.7 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares fell 5.01% to $0.3. The company's market cap stands at $9.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

NAOV

OCUP

QNCX

STSS

TIVC

VACC

ZYNE

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares increased by 7.4% to $0.91 during Wednesday's after-market session. The market value of their outstanding shares is at $33.0 million. </li>
<li>Science 37 Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCE#NASDAQ">SNCE</a>) stock rose 6.79% to $0.46. The market value of their outstanding shares is at $53.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) shares rose 5.74% to $0.41. The market value of their outstanding shares is at $34.4 million. </li>
<li>TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) shares increased by 5.55% to $1.9. The market value of their outstanding shares is at $45.7 million. </li>
<li>Minerva Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTRS#NASDAQ">UTRS</a>) stock rose 5.29% to $0.4. At the close, Minerva Surgical's trading volume reached 1.0 million shares. This is 135.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.0 million. </li>
<li>Hillstream BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HILS#NASDAQ">HILS</a>) stock rose 5.21% to $0.63. The market value of their outstanding shares is at $7.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ocuphire Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUP#NASDAQ">OCUP</a>) stock decreased by 30.9% to $2.6 during Wednesday's after-market session. This security traded at a volume of 304.2K shares come close, making up 123.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $54.0 million. </li>
<li>Paragon 28 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>) stock declined by 10.31% to $18.01. The market value of their outstanding shares is at $1.3 billion. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock fell 7.15% to $2.34. The company's market cap stands at $114.7 million. </li>
<li>Incannex Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares fell 7.05% to $3.3. The market value of their outstanding shares is at $201.1 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) stock fell 6.26% to $1.2. At the close, Cidara Therapeutics's trading volume reached 5.0 million shares. This is 842.3% of its average volume over the last 100 days. The company's market cap stands at $85.9 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares fell 5.01% to $0.41. This security traded at a volume of 121.6K shares come close, making up 52.5% of its average volume over the last 100 days. The company's market cap stands at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDTX

GTBP

HILS

IXHL

MNOV

MRKR

SNCE

TCRX

UTRS

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock rose 80.0% to $2.16 during Wednesday's pre-market session. The company's market cap stands at $6.7 million. </li>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) stock moved upwards by 28.05% to $5.66. The market value of their outstanding shares is at $5.6 million. </li>
<li>Incannex Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) stock increased by 23.74% to $3.96. The company's market cap stands at $241.3 million. </li>
<li>Aridis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDS#NASDAQ">ARDS</a>) shares increased by 17.85% to $0.99. The market value of their outstanding shares is at $25.7 million. </li>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares moved upwards by 17.33% to $8.8. The company's market cap stands at $157.9 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock increased by 13.72% to $0.58. The market value of their outstanding shares is at $8.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Axcella Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>) stock decreased by 23.3% to $0.46 during Wednesday's pre-market session. The company's market cap stands at $33.8 million. </li>
<li>Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) shares declined by 17.36% to $1.81. The market value of their outstanding shares is at $376.7 million. </li>
<li>Finch Therapeutics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNCH#NASDAQ">FNCH</a>) stock declined by 17.16% to $0.41. The market value of their outstanding shares is at $19.6 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares fell 13.47% to $0.4. The company's market cap stands at $1.9 million. </li>
<li>Baudax Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BXRX#NASDAQ">BXRX</a>) stock fell 10.79% to $3.72. The market value of their outstanding shares is at $2.0 million. </li>
<li>Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) shares declined by 8.91% to $235.0. The market value of their outstanding shares is at $83.0 billion. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDS

AXLA

BXRX

FNCH

FWBI

INMB

ISRG

PGEN

SNOA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sotera Health Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shc#NASDAQ">SHC</a>) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached agreements to settle the Ethylene Oxide cases pending against Sterigenics. Sterigenics will pay the company $408 million to settle the claims.</li>
<li>Party City Holdco Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prty#NYSE">PRTY</a>) gained 54% to $0.3193 following an Axios report suggesting The Franchise Group could be looking at acquiring the company.</li>
<li>Panbela Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbla#NASDAQ">PBLA</a>) shares rose 51.1% to $0.1224 after gaining 4% on Monday.</li>
<li>VYNE Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vyne#NASDAQ">VYNE</a>) climbed 50.5% to $0.2892 after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201.</li>
<li>Elys Game Technology, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elys#NASDAQ">ELYS</a>) jumped 49.5% to $0.6276.</li>
<li>Boxed, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/boxd#NYSE">BOXD</a>) gained 36.6% to $0.5191 after the company announced its Spresso Saas modular solution platform is now available on Google Cloud.</li>
<li>Biora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bior#NASDAQ">BIOR</a>) rose 35% to $2.85. HC Wainwright &amp; Co. maintained Biora Therapeutics with a Buy.</li>
<li>DermTech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dmtk#NASDAQ">DMTK</a>) shares climbed 32.6% to $2.88 after DermTech announced the foundational assay of its DermTech Melanoma Test (DMT) is recommended for coverage by TRICARE.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) gained 31.7% to $0.48 after the company announced a $2 million stock repurchase plan.</li>
<li>POET Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/poet#NASDAQ">POET</a>) gained 31.3% to $4.2750.</li>
<li>Jianzhi Education Technology Group Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jz#NASDAQ">JZ</a>) gained 30% to $1.5657.</li>
<li>Rubius Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ruby#NASDAQ">RUBY</a>) jumped 29.4% to $0.2349.</li>
<li>Oak Street Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/osh#NYSE">OSH</a>) gained 28.4% to $28.99 as CVS Health is reportedly exploring an acquisition of primary care center operator.</li>
<li>BTCS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcs#NASDAQ">BTCS</a>) jumped 28.2% to $1.3199 after the company launched a private beta of its digital asset analytic and staking-as-a-service platform StakeSeeker.</li>
<li>Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) rose 27.1% to $14.40. Frontline announced termination of combination agreement with Euronav.</li>
<li>Schmitt Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smit#NASDAQ">SMIT</a>) gained 27.1% to $0.3879.</li>
<li>Prenetics Global Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pre#NASDAQ">PRE</a>) gained 25.6% to $2.3880 after the company announced its ACT Genomics received clearance from the FDA for ACTOnco.</li>
<li>NeuroPace, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/npce#NASDAQ">NPCE</a>) jumped 25.2% to $2.04. NeuroPace announced preliminary unaudited Q4 revenue of $12.8 million and FY22 revenue of $45.5 million.</li>
<li>Bright Health Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhg#NYSE">BHG</a>) gained 24% to $0.8050 after the company announced it increased 2023 Enterprise Revenue guidance to $3.4 - $3.6 billion.</li>
<li>Frequency Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/freq#NASDAQ">FREQ</a>) rose 24% to $4.13.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) jumped 23.5% to $2.62.</li>
<li>Accolade, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/accd#NASDAQ">ACCD</a>) rose 23.5% to $9.58 after the company reported better-than-expected Q3 EPS and sales results and issued FY23 revenue guidance above estimates.</li>
<li>Kura Sushi USA, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krus#NASDAQ">KRUS</a>) gained 21.4% to $52.24. Kura Sushi recently reported worse-than-expected Q1 EPS and sales results.</li>
<li>Titan Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdi#NASDAQ">TMDI</a>) rose 20.4% to $1.1195.</li>
<li>Tuesday Morning Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tuem#NASDAQ">TUEM</a>) gained 19.4% to $0.74.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) climbed 17.8% to $4.4438. Summit Therapeutics said on January 6, 2023, the company held meeting to vote on increase number of authorized shares of common stock by 650 million shares.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) gained 17.2% to $1.7350 after the company reported preliminary Q4 and FY22 revenue results above estimates.</li>
<li>Bed Bath &amp; Beyond Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbby#NASDAQ">BBBY</a>) rose 17.1% to $1.8975 despite the company turning in worse-than-expected financial results.</li>
<li>Satixfy Communications Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/satx#NYSE">SATX</a>) gained 16.3% to $7.49.</li>
<li>Versus Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vs#NASDAQ">VS</a>) rose 15.3% to $0.6990 after jumping over 16% on Monday.</li>
<li>CureVac N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvac#NASDAQ">CVAC</a>) gained 14.8% to $11.90.</li>
<li>Vericel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcel#NASDAQ">VCEL</a>) rose 14% to $27.25 after the company reported preliminary FY22 revenue results.</li>
<li>Rain Oncology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rain#NASDAQ">RAIN</a>) gained 13.9% to $13.23.</li>
<li>Oatly Group AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otly#NASDAQ">OTLY</a>) jumped 12.3% to $2.6750 after the company announced an expansion of its partnership with Reitan to feature oat drink in coffee machines in its 7-Eleven and Pressbyr&aring;n convenience stores across Sweden.</li>
<li>Comstock Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lode#NYSE">LODE</a>) shares rose 11.9% to $0.4498.</li>
<li>Heska Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hska#NASDAQ">HSKA</a>) gained 10.3% to $74.34. Heska CEO and President Kevin S Wilson bought a total of 11,018 shares at an average price of $58.62.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Peak Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pkbo#NASDAQ">PKBO</a>) dropped 58.2% to $2.09.</li>
<li>BioAtla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcab#NASDAQ">BCAB</a>) shares fell 46.2% to $4.1550 after the company provided clinical program updates and upcoming 2023 milestones.</li>
<li>BIOLASE, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biol#NASDAQ">BIOL</a>) fell 46.5% to $0.3705 after the company announced pricing of $9.75 million offering.</li>
<li>Rayonier Advanced Materials Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ryam#NYSE">RYAM</a>) fell 30.6% to $6.35. RBC Capital downgraded Rayonier Adv</li>
<li>Materials from Outperform to Sector Perform and lowered the price target from $9 to $8.</li>
<li>Calithera Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cala#NASDAQ">CALA</a>) dipped 25.3% to $0.4931. Calithera Biosciences shares dipped around 82% on Monday after its board of directors determined to dissolve the company and liquidate its assets. Also, the company will discontinue all clinical development programs and reduce its workforce.</li>
<li>Idera Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idra#NASDAQ">IDRA</a>) fell 17.6% to $0.5510.</li>
<li>Euronav NV (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eurn#NYSE">EURN</a>) shares fell 16.9% to $13.24.</li>
<li>IsoPlexis Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iso#NASDAQ">ISO</a>) dipped 15.3% to $1.33.</li>
<li>Lucira Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lhdx#NASDAQ">LHDX</a>) dropped 14.8% to $0.3438.</li>
<li>Midatech Pharma plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtp#NASDAQ">MTP</a>) fell 14.7% to $0.81.</li>
<li>Berkeley Lights, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bli#NASDAQ">BLI</a>) dropped 13.7% to $2.2850 after the company issued FY22 revenue guidance below analyst estimates.</li>
<li>ALX Oncology Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxo#NASDAQ">ALXO</a>) fell 12% to $9.22.</li>
<li>Virgin Orbit Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vorb#NASDAQ">VORB</a>) fell 11.7% to $1.70. Virgin Orbit shared its readiness for the Start Me Up mission for a historic U.K. launch on January 9.</li>
<li>G Medical Innovations Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmvd#NASDAQ">GMVD</a>) fell 10.9% to $3.9812 after jumping 42% on Monday.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) fell 9.5% to $1.2850.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) fell 8.4% to $77.67 after Spruce Point Management issued a bearish report on the stock.</li>
<li>Apexigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apgn#NASDAQ">APGN</a>) fell 7.2% to $1.67 after gaining around 91% on Monday.</li>
<li>Box, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/box#NYSE">BOX</a>) fell 6.3% to $27.96. RBC Capital downgraded Box from Sector Perform to Underperform and lowered the price target from $28 to $24.</li>
</ul>
Also Check This Out <a href="https://www.benzinga.com/markets/cryptocurrency/23/01/30355338/ethereum-remains-above-this-key-level-aptos-emerges-as-top-gainer"> Ethereum Remains Above This Key Level; Aptos Emerges As Top Gainer </a>

Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) stock moved upwards by 86.9% to $16.15 during Tuesday's regular session. The current volume of 38.4 million shares is 1927.9% of Sotera Health's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $4.5 billion. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock increased by 54.32% to $0.3. As of 12:30 EST, this security is trading at a volume of 30.1 million shares, making up 5096.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.1 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares rose 39.81% to $2.95. As of 12:30 EST, Biora Therapeutics's stock is trading at a volume of 5.3 million, which is 6281.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $26.3 million. </li>
<li>DermTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) shares moved upwards by 34.86% to $2.94. DermTech's stock is trading at a volume of 1.6 million shares as of 12:30 EST. This is 308.4% of its average full-day volume over the last 100 days. The company's market cap stands at $88.8 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares rose 32.79% to $2.47. Prenetics Global's stock is trading at a volume of 38.7 million shares as of 12:30 EST. This is 57077.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $293.5 million. </li>
<li>Rubius Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUBY#NASDAQ">RUBY</a>) stock moved upwards by 29.49% to $0.23. Rubius Therapeutics's stock is trading at a volume of 6.3 million shares as of 12:30 EST. This is 599.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock decreased by 46.5% to $0.37 during Tuesday's regular session. The current volume of 2.9 million shares is 1969.7% of Biolase's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $2.6 million. </li>
<li>Peak Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKBO#NASDAQ">PKBO</a>) stock decreased by 41.77% to $2.05. The market value of their outstanding shares is at $41.1 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares fell 25.24% to $0.49. The current volume of 1.8 million shares is 1432.4% of Calithera Biosciences's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $2.4 million. </li>
<li>Lucira Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>) shares declined by 15.06% to $0.34. Trading volume for Lucira Health's stock is 1.7 million as of 12:30 EST. This is 40.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.9 million. </li>
<li>ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares decreased by 14.92% to $8.92. The current volume of 166.1K shares is 99.6% of ALX Oncology Holdings's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $363.3 million. </li>
<li>Midatech Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTP#NASDAQ">MTP</a>) stock decreased by 14.74% to $0.81. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock rose 74.7% to $3.25 during Tuesday's pre-market session. The market value of their outstanding shares is at $386.2 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) shares increased by 69.89% to $0.33. The market value of their outstanding shares is at $18.9 million. </li>
<li>Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) shares rose 66.66% to $14.4. The company's market cap stands at $4.0 billion. </li>
<li>Oak Street Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSH#NYSE">OSH</a>) stock rose 36.28% to $30.76. The market value of their outstanding shares is at $7.4 billion. </li>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) stock moved upwards by 27.04% to $2.02. The company's market cap stands at $74.8 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVBU#NASDAQ">REVBU</a>) shares rose 25.0% to $0.3. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock declined by 42.2% to $0.4 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>G Medical Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMVD#NASDAQ">GMVD</a>) shares fell 19.32% to $3.55. The company's market cap stands at $3.5 million. </li>
<li>Calithera Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>) shares decreased by 16.7% to $0.55. The market value of their outstanding shares is at $2.6 million. </li>
<li>Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) stock declined by 14.72% to $176.8. The company's market cap stands at $27.8 billion. </li>
<li>Apexigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGN#NASDAQ">APGN</a>) shares declined by 13.89% to $1.55. The company's market cap stands at $34.9 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares decreased by 10.92% to $0.71. The company's market cap stands at $57.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ILMN

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

REVBU

VTVT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>VYNE Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vyne#NASDAQ">VYNE</a>) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo patient was dosed in Phase 1a/b clinical trial of novel BET inhibitor VYN201.</li>
<li>Panbela Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbla#NASDAQ">PBLA</a>) shares rose 45.4% to $0.1178 in pre-market trading after gaining 4% on Monday.</li>
<li>Sotera Health Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shc#NASDAQ">SHC</a>) rose 42.7% to $12.33 in pre-market trading after the company reported settlement of ethylene oxide litigation in Illinois.</li>
<li>Oak Street Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/osh#NYSE">OSH</a>) shares rose 33.1% to $30.04 in pre-market trading. CVS Health Corp is in talks to buy Oak Street Health, Bloomberg News reported.</li>
<li>Versus Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vs#NASDAQ">VS</a>) rose 32.7% to $0.8039 in pre-market trading after jumping over 16% on Monday.</li>
<li>Nuwellis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuwe#NASDAQ">NUWE</a>) rose 23.4% to $11.50 in pre-market trading after gaining 11% on Monday. Nuwellis indicated that preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, which shows an increase of 42% and 8% over the same periods last year.</li>
<li>Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) rose 19.5% to $13.54 in pre-market trading. Frontline announced termination of combination agreement with Euronav.</li>
<li>Comstock Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lode#NYSE">LODE</a>) shares rose 14.5% to $0.4607 in pre-market trading.</li>
<li>Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) rose 14.3% to $0.3006 in pre-market trading after dropping 12% on Monday. Swvl recently announced the commencement of a strategic review process.</li>
<li>Bed Bath &amp; Beyond Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbby#NASDAQ">BBBY</a>) rose 11.1% to $1.80 in pre-market trading after surging around 24% on Monday. The company is scheduled to release quarterly earnings today.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Virgin Orbit Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vorb#NASDAQ">VORB</a>) fell 20.7% to $1.53 in pre-market trading. Virgin Orbit shared its readiness for the Start Me Up mission for a historic U.K. launch on January 9.</li>
<li>G Medical Innovations Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmvd#NASDAQ">GMVD</a>) fell 17.3% to $3.64 in pre-market trading after jumping 42% on Monday.</li>
<li>Euronav NV (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eurn#NYSE">EURN</a>) shares fell 17.1% to $13.21 in pre-market trading.</li>
<li>Calithera Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cala#NASDAQ">CALA</a>) fell 13.6% to $0.57 in pre-market. Calithera Biosciences shares dipped around 82% on Monday after its board of directors determined to dissolve the company and liquidate its assets. Also, the company will discontinue all clinical development programs and reduce its workforce.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) fell 12.9% to $4.85 in pre-market trading after jumping around 22% on Friday.</li>
<li>Bitfarms Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bitf#NASDAQ">BITF</a>) fell 12.4% to $0.5872 in pre-market trading after jumping 23% on Monday.</li>
<li>Apexigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apgn#NASDAQ">APGN</a>) fell 11.1% to $1.60 in pre-market trading after gaining around 91% on Monday.</li>
<li>Freight Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frgt#NASDAQ">FRGT</a>) fell 8.5% to $0.2201 in pre-market trading. The company expects 2023 revenue to be between $36 million and $42 million.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) fell 8.5% to $1.30 in pre-market trading.</li>
<li>Astra Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astr#NASDAQ">ASTR</a>) shares fell 8.4% to $0.4157 in pre-market trading.</li>
</ul>

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday.
The Dow traded up 0.14% to 33,678.48 while the NASDAQ rose 1.63% to 10,741.65. The S&amp;P 500 also rose, gaining, 0.63% to 3,919.83.
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/23/01/30333848/bitcoin-tops-this-key-level-gala-solana-among-top-gainers"> Bitcoin Tops This Key Level; Gala, Solana Among Top Gainers</a>

Leading and Lagging Sectors

Information technology shares gained by 2.8% on Monday. Meanwhile, top gainers in the <a href='https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/'>sector</a> included Duck Creek Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dct#NASDAQ">DCT</a>), up 47%, and Bitfarms Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bitf#NASDAQ">BITF</a>), up 34%.

In trading on Monday, health care shares fell by 0.5%.

Top Headline

Acuity Brands, Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ayi#NYSE">AYI</a>) reported better-than-expected earnings and sales results for its first quarter.

Acuity Brands reported first-quarter FY23 net sales growth of 7.8% year-over-year to $997.9 million, beating the consensus of $984.5 million. Adjusted EPS of $3.29 beat the consensus of $3.00.
&nbsp;

Equities Trading UP
&nbsp;
<ul>
<li>CinCor Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cinc#NASDAQ">CINC</a>) shares shot up 147% to $29.04 after AstraZeneca announced it will acquire the company for $26 per share in cash.</li>
<li>Shares of Amryt Pharma plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amyt#NASDAQ">AMYT</a>) got a boost, shooting 108% to $14.60 after Chiesi Farmaceutici announced it will acquire the company for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS.</li>
<li>Albireo Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/albo#NASDAQ">ALBO</a>) shares were also up, gaining 93% to $43.94 after Ipsen announced it will acquire the company for $42 per share plus a contingent value right of $10 per share.</li>
</ul>

&nbsp;
Equities Trading DOWN
<ul>
<li>Calithera Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cala#NASDAQ">CALA</a>) shares tumbled 81% to $30.81. Calithera Biosciences announced board approval of complete liquidation and dissolution.</li>
<li>Shares of Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) were down 24% to $30.81 after the company reported preliminary unaudited financial results for FY22. The company expects to report revenue in the range of $252 million to $253 million for FY22.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) was down, falling 22% to $2.9350. Cerus sees preliminary Q4 product revenues of $44 million, up 10% year over year.</li>
</ul>


Also Check This Out: <a href="https://www.benzinga.com/markets/asia/23/01/30331244/why-market-expert-says-its-time-to-buy-north-asian-stock-sectors"> Why Market Expert Says It&#39;s Time To Buy North Asian Stock Sectors</a>

Commodities
In commodity news, oil traded up 1.6% to $74.98 while gold traded up 0.6% at $1,880.20.

Silver traded down 0.1% to $23.96 on Monday while copper rose 3.2% to $4.0375.
Euro zone

European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 gained 0.88%, London&rsquo;s FTSE 100 gained 0.33% while Spain&rsquo;s IBEX 35 Index slipped 0.07%. The German DAX gained 1.25%, French CAC 40 climbed 0.68% and Italy&rsquo;s FTSE MIB Index gained 0.81%.

The Eurozone&rsquo;s unemployment rate came in unchanged at 6.5% for November from the prior month&#39;s all-time low level, while unemployment rate in Italy declined to 7.8% in November.

France&rsquo;s current account deficit increased to EUR 6.8 billion in November versus a revised EUR 3.4 billion in the prior month, while trade deficit increased to EUR 13.8 billion in November. Industrial production in Germany rose 0.2% month-over-month in November.
&nbsp;

Asia Pacific Markets

Asian markets closed higher on Monday, with the Hong Kong&rsquo;s Hang Seng Index climbing 1.89%, and China&rsquo;s Shanghai Composite Index adding 0.58%.

Private house approvals in Australia declined 2.2% month-over-month to 9,142 units in November, while building permits declined by 9% month-over-month to 13,898 units in November.
&nbsp;
Economics

Data on consumer credit for November will be released at 3:00 p.m. ET.
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/01/30325823/fear-greed-index-moves-to-neutral-zone-following-jobs-data"> Fear &amp; Greed Index Moves To &#39;Neutral&#39; Zone Following Jobs Data</a>

COVID-19 Update
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 103,086,920 cases with around 1,121,090 deaths. India confirmed a total of at least 44,681,170 cases and 530,720 deaths, while France reported over 39,407,720 COVID-19 cases with 162,640 deaths. In total, there were at least 668,796,070 cases of COVID-19 worldwide with more than 6,714,170 deaths.

S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher

<h3>Gainers</h3>
<ul>
<li>CinCor Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cinc#NASDAQ">CINC</a>) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.</li>
<li>Apexigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apgn#NASDAQ">APGN</a>) jumped 111% to $1.99 after climbing more than 10% on Friday.</li>
<li>Amryt Pharma plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amyt#NASDAQ">AMYT</a>) gained 106.7% to $14.49 after Chiesi Farmaceutici announced it will acquire the company for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS.</li>
<li>Albireo Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/albo#NASDAQ">ALBO</a>) shares climbed 92.9% to $44.03 after Ipsen announced it will acquire the company for $42 per share plus a contingent value right of $10 per share.</li>
<li>Duck Creek Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dct#NASDAQ">DCT</a>) gained 47% to $19.10 after the company agreed to be acquired by Vista Equity Partners for $2.6 billion.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) surged 43% to $28.25 as the company reported the FDA acceptance Of supplemental Biologics License Application for DAXXIFY for injection for the treatment of cervical dystonia.</li>
<li>Novo Integrated Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvos#NASDAQ">NVOS</a>) rose 35.9% to $0.2052. Novo Integrated Sciences recently reported it entered an agreement to purchase 100% of shares of SWAG in exchange for $1.00.</li>
<li>Sema4 Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfr#NASDAQ">SMFR</a>) gained 34% to $0.3299. Sema4 sees preliminary 2022 pro-forma revenues of $170 million to $173 million.</li>
<li>Comera Life Sciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmra#NASDAQ">CMRA</a>) gained 32% to $2.02. Comera Life Sciences 10% owner Charles Cherington bought a total of 743,243 shares at an average price of $1.23.</li>
<li>Party City Holdco Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prty#NYSE">PRTY</a>) climbed 31.9% to $0.2363. Party City shares dropped 50% on Friday following a report suggesting the company has hired a restructuring advisor and plans a bankruptcy filing within weeks.</li>
<li>Bed Bath &amp; Beyond Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbby#NASDAQ">BBBY</a>) rose 30.9% to $1.7150. Bed Bath &amp; Beyond shares dropped over 22% on Friday following a report indicating the company could file for bankruptcy in the coming weeks.</li>
<li>CureVac N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvac#NASDAQ">CVAC</a>) shares rose 30.4% to $10.77. CureVac shares jumped over 29% on Friday after the company announced data on joint COVID-19 and flu mRNA vaccine development programs.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) jumped 28% to $2.06.</li>
<li>Better Choice Company Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bttr#NYSE">BTTR</a>) gained 28% to $0.7293.</li>
<li>Hempacco Co., Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hpco#NASDAQ">HPCO</a>) rose 28% to $1.19.</li>
<li>Bit Digital, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btbt#NASDAQ">BTBT</a>) gained 28% to $0.9498. Bit Brother regained compliance with Nasdaq minimum bid price requirements for continued listing.</li>
<li>Celyad Oncology SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyad#NASDAQ">CYAD</a>) jumped 25.1% to $0.7482. Celyad Oncology recently reported it has decided to discontinue the development of its remaining clinical program CYAD-211.</li>
<li>Paya Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/paya#NASDAQ">PAYA</a>) gained 24.5% to $9.70 after Nuvei entered into a definitive agreement to acquire the company for $9.75 per share in cash.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lx#NASDAQ">LX</a>) jumped 24.5% to $2.9892.</li>
<li>Xos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xos#NASDAQ">XOS</a>) jumped 23.3% to $1.00.</li>
<li>NanoString Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nstg#NASDAQ">NSTG</a>) surged 23.1% to $9.77. NanoString issued preliminary financial and operational highlights for Q4 and FY 2022.</li>
<li>Greenidge Generation Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gree#NASDAQ">GREE</a>) gained 22.1% to $0.4780.</li>
<li>Barfresh Food Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brfh#NASDAQ">BRFH</a>) gained 21.1% to $1.49.</li>
<li>Grove Collaborative Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grov#NYSE">GROV</a>) jumped 20.6% to $0.5790.</li>
<li>Exact Sciences Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>) gained 20.5% to $56.85 after the company announced preliminary Q4 results.</li>
<li>Tempo Automation Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmpo#NASDAQ">TMPO</a>) jumped 20% to $1.26.</li>
<li>Kronos Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kron#NASDAQ">KRON</a>) jumped 19.7% to $2.06. Kronos Bio announced discovery collaboration with Genentech to advance novel therapies against transcriptional targets in oncology.</li>
<li>Bitfarms Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bitf#NASDAQ">BITF</a>) gained 19.4% to $0.65.</li>
<li>Guardion Health Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ghsi#NASDAQ">GHSI</a>) jumped 19.4% to $7.10.</li>
<li>Lufax Holding Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lu#NYSE">LU</a>) jumped 17.5% to $2.5400.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) gained 15.5% to $4.7250. Jefferies downgraded Marathon Digital from Buy to Hold and announced a $4 price target.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) rose 12.5% to $37.42. Jefferies initiated coverage on Coinbase Global with a Hold rating and announced a price target of $35.</li>
<li>Riot Blockchain, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) gained 12% to $4.78. Wells Fargo maintained Riot Platforms with an Equal-Weight and lowered the price target from $6 to $5.</li>
<li>Viracta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/virx#NASDAQ">VIRX</a>) rose 10.3% to $1.81 after the company announced first clinical response in epstein-barr virus-positive (EBV+) solid tumor setting.</li>
<li>Zillow Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/z#NASDAQ">Z</a>) gained 8.7% to $39.01 after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $22 to $42.</li>
<li>Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) jumped 8.3% to $122.44 amid vehicle price cuts in China and indications that wait times for some Chinese Model Y vehicles have increased.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) rose 8% to $133.93. Piper Sandler maintained Snowflake with an Overweight and lowered the price target from $200 to $194.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Calithera Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cala#NASDAQ">CALA</a>) shares dipped 80.1% to $0.72. Calithera Biosciences announced board approval of complete liquidation and dissolution.</li>
<li>MultiMetaVerse Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmv#NASDAQ">MMV</a>) fell 58.4% to $4.81 after jumping 82% on Friday.</li>
<li>Moolec Science SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlec#NASDAQ">MLEC</a>) fell 41.3% to $11.30 after jumping 258% on Friday.</li>
<li>Peak Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pkbo#NASDAQ">PKBO</a>) dropped 28.8% to $2.5910.</li>
<li>Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) fell 23.4% to $30.97 after the company reported preliminary unaudited financial results for FY22. The company expects to report revenue in the range of $252 million to $253 million for FY22.</li>
<li>AMTD Digital Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hkd#NYSE">HKD</a>) dropped 20.6% to $18.20.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) fell 20.5% to $3.0060. Cerus sees preliminary Q4 product revenues of $44 million, up 10% year over year.</li>
<li>Golden Sun Education Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gsun#NASDAQ">GSUN</a>) declined 19.5% to $1.8060.</li>
<li>Magic Empire Global Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/megl#NASDAQ">MEGL</a>) dropped 19.5% to $2.23.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) fell 18.6% to $30.41. Takeda Pharmaceutical Co and Arrowhead Pharmaceuticals announced topline results from the Phase 2 SEQUOIA study of fazirsiran (TAK-999/ARO-AAT) for liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) dropped 17% to $0.8720.</li>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) declined 17% to $6.57. Monte Rosa Therapeutics outlined progress across portfolio of molecular glue degraders and key anticipated milestones for 2023.</li>
<li>Arvinas, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arvn#NASDAQ">ARVN</a>) dropped 15.8% to $28.68. Arvinas said the company and Pfizer have proposed a modification to planned Veritac-3 Phase 3 study.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 14.8% to $0.7999.</li>
<li>Harmony Biosciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrmy#NASDAQ">HRMY</a>) dropped 14.4% to $45.92. Harmony Biosciences named Jeffrey M. Dayno, MD as interim CEO and expands role of Jeff Aronin to executive chairman.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) fell 11.2% to $10.50 after the company reported preliminary FY22 ORLADEYO net revenue results and issued FY23 ORLADEYO net revenue guidance.</li>
<li>VYNE Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vyne#NASDAQ">VYNE</a>) fell 9.3% to $0.2051 after jumping around 28% on Friday. VYNE Therapeutics, during November, posted a Q3 loss of $0.16 per share.</li>
<li>Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) fell 8.8% to $0.5901 after jumping around 35% on Friday. Neptune recently announced receipt of NASDAQ notification.</li>
<li>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crbp#NASDAQ">CRBP</a>) shares fell 8% to $0.1334 after gaining over 10% on Friday.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) fell 7.7% to $20.42 after the company issued Q4 adjusted EPS and sales guidance.</li>
</ul>
Also Check This Out <a href="https://www.benzinga.com/markets/cryptocurrency/23/01/30333848/bitcoin-tops-this-key-level-gala-solana-among-top-gainers"> Bitcoin Tops This Key Level; Gala, Solana Among Top Gainers</a>

Comments

Calithera Biosciences

Calithera Biosciences (CALA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga